Professor Vilmos Fulop of the University of Warwick in the UK is the recipient of the first Domainex Discovery STAR Award.
This award will give Professor Fulop access to Domainex’s drug discovery capabilities to support his research for a new treatment for Chagas disease. No financial details have been released.
'Domainex received many strong applications to its Discovery STAR award scheme, but Professor Fulop’s project stood out as he had all the elements needed to start a drug discovery project in this area of unmet medical need,' said Eddy Littler, Chief Executive of Domainex. 'We very much look forward to helping Professor Fulop to identify inhibitors of his drug target, and hope that in doing so he will be able to access further funding that will support our joint efforts towards finding a new cure for this terrible disease.'
Domainex will provide Professor Fulop with drug discovery guidance and exclusive access to its LeadBuilder virtual hit screening technology.
Following the identification of hits using this approach, Professor Fulop will seek additional funding to progress his work.
I regard this collaboration as a starting point towards making significant steps in finding a new cure for the treatment of neglected Chagas
Professor Fulop said: ‘I am absolutely delighted with this award and looking forward to working with Domainex. I regard this collaboration as a starting point towards making significant steps in the finding of a new cure for the treatment of neglected Chagas and the related African sleeping sickness disease.’
Domainex launched its Discovery STAR Award to support early drug discovery. The scheme provides successful applicants with virtual hit screening using Domainex’s LeadBuilder platform and/or drug discovery consultancy services. The aim is to bridge a current ‘funding gap’ for these activities, thereby allowing projects to progress to a point that is suitable for larger external grant-funding schemes such as the TSB/MRC Biomedical Catalyst Fund, The Wellcome Trust’s SDDI scheme, European Union FP7, and MRC DPFS.
Domainex is based on the Cambridge Science Park, UK and has offices in the London Bioscience Innovation Centre.
